A scientific statement has been published by the AHA regarding the relationship between alcohol use and cardiovascular disease.

The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily ...

Dr Amal Mattu breaks down the key updates — and lingering pitfalls — in the 2025 ACS guidelines that every acute care ...